Cytosystems Ltd

Add Favorites Contact Author

cytosystems

We believe in an alternative

That’s why we’re re-inventing urine cytology.

The Company

Cytosystems develops non-invasive cancer diagnostic and stratification products, with an emphasis on a whole-cell approach.  Based on ground-breaking research at the University of Cambridge, UK, Cytosystems works with clinicians and pathology laboratories to take technologies from bench research to a clinical product for the benefit of patients.  Cytosystems has developed a patent portfolio of enabling technologies for the diagnosis and management of patients with urological cancers.

BladderLightTM

Cytosystems’ first proprietary product, BladderLight™, redefines the potential of urine cytology in the diagnosis and management of patients with bladder cancer.

The benefits include: improved cell collection and preservation sensitive and specific molecular marker whole-cell approach digitized analysis

Clinical evidence

 

  Cytosystems Ltd Cystoscopy Cytology Leading molecular competitor
  Initial diagnosis Surveillance for recurrence
Sensitivity 97% 89% 92% 35% 62%
Specificity 90% 92% 88% 79% 90%
Source: (Recent clinical trial comprising 247 patients.  Total patients involved in optimizing assay >1000.) (Canadian Journal of Urology) (Cancer Cytopathology)

Pipeline

Non-invasive diagnostic technologies for other cancers are currently under development.  Cytosystems is actively involved in major multi-disciplinary clinical research projects with leading international urological cancer institutions.

Call to Action

We are always looking for new partners to collaborate with to develop new clinically applied technologies for the benefit of patients and healthcare professionals.  Contact us at info@cytosystems.com.

Address Cytosystems Ltd, Cruickshank Building, Craibstone, Aberdeen AB21 9TR Phone: +44 (0)1224 711375 Fax: +44 (0)1224 713968 Email info@cytosystems.com. Web: www.cytosystems.com

The project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 673664 plus co-funding by Innovate UK, the UK’s innovation agency.

 


Category